Home > Publications database > Fundamentals of immune resistance in cancer. [Grundlagen der Immunresistenz onkologischer Erkrankungen]. > print

001     304460
005     20251024115534.0
024 7 _ |a 10.1007/s00761-025-01776-3
|2 doi
024 7 _ |a 2731-7226
|2 ISSN
024 7 _ |a 0947-8965
|2 ISSN
024 7 _ |a 1433-0415
|2 ISSN
024 7 _ |a 2731-7234
|2 ISSN
037 _ _ |a DKFZ-2025-01853
082 _ _ |a 610
100 1 _ |a Halama, Niels
|0 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601
|b 0
|e First author
|u dkfz
245 _ _ |a Fundamentals of immune resistance in cancer. [Grundlagen der Immunresistenz onkologischer Erkrankungen].
260 _ _ |a New York
|c 2025
|b Springer Medizin
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761206919_2347374
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D196#LA:D196# / Volume 31, pages 971–979, (2025)
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: inrepo02.dkfz.de
700 1 _ |a Grauling-Halama, Silke
|0 P:(DE-He78)7782f484a2739525e57db71b52079d5f
|b 1
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00761-025-01776-3
|0 PERI:(DE-600)3120761-3
|p 971–979
|t Die Onkologie
|v 31
|y 2025
|x 2731-7226
909 C O |o oai:inrepo02.dkfz.de:304460
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)7782f484a2739525e57db71b52079d5f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONKOLOGIE-GER : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
920 2 _ |0 I:(DE-He78)D196-20160331
|k D196
|l Translationale Immuntherapie
|x 0
920 1 _ |0 I:(DE-He78)D196-20160331
|k D196
|l Translationale Immuntherapie
|x 0
920 0 _ |0 I:(DE-He78)D196-20160331
|k D196
|l Translationale Immuntherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D196-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21